Retinitis Pigmentosa Treatment | Market Size, Share & Growth Report 2025-2033
The Retinitis Pigmentosa Treatment Market Report is Segmented by Treatment Type (Gene Therapy, Stem Cell Therapy, Medications, Vitamin Supplements, and Others), End-User (Hospitals, Specialty Clinics, Research Institutes, and Others), Route of Administration (Oral, Injectable, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others).
Retinitis Pigmentosa Treatment Market
Market Analysis
How the market stands today, and what is shaping it
The global retinitis pigmentosa treatment market was estimated at approximately USD 3.50 billion in 2025 and is projected to reach around USD 5.92 billion by 2033, representing a CAGR of approximately 6.80% during 2025–2033, based on Core Market Research estimates. Care consists overwhelmingly of supplementation, periodic retinal assessment and treatment of complications, with one approved gene therapy, voretigene neparvovec, available only to patients with biallelic RPE65 mutations. Growth is supported by a progressive and irreversible condition requiring lifelong management, by an optogenetic therapy with a rolling Biologics License Application underway that works independently of the causative mutation, and by a phase 3 programme in X-linked disease. Expansion is constrained by genetic heterogeneity that fragments the population into subsets too small to develop against, by eligibility depending on genetic testing that is unevenly available, and by subretinal delivery restricting treatment to specialist centres. Competition turns on how much of the population an approach can reach rather than on comparative efficacy.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Retinitis pigmentosa is progressive and irreversible, so patients remain under lifelong ophthalmic management whether or not a mutation-specific therapy exists. Prevalence of 11.09 to 26.43 per 100,000 sustains continuing demand for monitoring, supplementation and treatment of complications.
- Optogenetic therapy bypasses the genetic cause entirely. MCO-010 uses a bioengineered opsin delivered in an AAV2 vector to bipolar cells where photoreceptors have been lost, creating light sensitivity independently of which mutation caused the degeneration.
- A rolling Biologics License Application for optogenetic therapy in retinitis pigmentosa is underway, supported by Fast Track and Orphan Drug designations. A second approved product would be the first since 2017 and the first not restricted to one mutation.
- The FDA granted Fast Track designation to AAV-RPGR for X-linked disease, and a phase 3 randomised controlled study is actively dosing. X-linked RPGR disease is a substantially larger genetic subset than RPE65, so approval would widen the addressable population considerably.
- A single intravitreal injection is a materially simpler procedure than subretinal delivery during vitrectomy. Treatment that does not require a vitreoretinal surgical centre could be given at far more sites, which changes where and how many patients can be reached.
Market Challenges
- The stored figures were previously USD 12.6 billion for 2024 rising to USD 24.1 billion, which matched a published estimate rather than the clinical reality. They have been recalculated to USD 3.50 billion for 2025 against the lowest published anchor and the prevalence and treatment evidence described in this report.
- Only one approved therapy exists and it serves a fraction of patients. Voretigene neparvovec treats biallelic RPE65 mutations, which account for between 0.23% and 4.27% of retinitis pigmentosa cases, leaving the great majority with no mutation-specific option.
- The disease is genetically heterogeneous, so a gene replacement approach must be developed separately for each causative gene. That fragments an already rare population into subsets too small to support independent commercial development for most of them.
- Eligibility depends on genetic confirmation. A patient who is not tested cannot be identified as a candidate for the one approved product, so uneven access to genetic diagnosis limits the treatable population independently of whether the therapy is available.
- Delivery is a constraint in itself. Subretinal administration during vitrectomy restricts treatment to centres with vitreoretinal surgical capability, and published work notes that delivery and immune complications have both hindered development across the field.
Opportunities
- Mutation-agnostic approaches could reach the majority of patients that gene replacement cannot. Optogenetic therapy restores light sensitivity through bipolar cells regardless of which gene caused photoreceptor loss, which sidesteps the heterogeneity that fragments the field.
- X-linked disease associated with RPGR variants is a considerably larger subset than RPE65. An approval there would multiply the addressable population for mutation-specific therapy several times over rather than adding incrementally to it.
- Photovoltaic subretinal implants have shown clinically meaningful improvement in 81% of participants with geographic atrophy at 12 months, and evaluation is extending to inherited retinal disease. A device route would serve advanced patients whom no gene therapy can help.
- Intravitreal delivery could widen the treating site base well beyond vitreoretinal surgical centres, which is currently one of the tightest constraints on how many patients any approved therapy can reach.
- Wider genetic testing in inherited retinal disease would identify eligible patients who are currently undiagnosed at the mutation level, converting prevalent patients into treatable ones without requiring any new product.
Trends and Insights
Key market trends shaping the industry landscape
Value and Attention Sit in Different Places
High impactLong-termOne approved gene therapy serves 0.23% to 4.27% of cases, while most patients are managed with supplementation, monitoring and treatment of complications.
Insight: Almost all spending in this market is supportive care rather than disease-modifying treatment, which is why published market sizes built on gene therapy pricing overstate it so heavily.
Mutation-Agnostic Approaches Are Advancing Fastest
High impactMid-termAn optogenetic therapy working through bipolar cells irrespective of the causative gene has a rolling Biologics License Application underway, with five-year safety data.
Insight: Genetic heterogeneity makes gene-by-gene replacement commercially impractical for most subsets, so approaches indifferent to the mutation have a structural advantage rather than merely a scientific one.
Delivery Route Is a Commercial Variable
Medium impactMid-termThe approved therapy requires subretinal delivery during vitrectomy while the leading candidate uses a single intravitreal injection.
Insight: The number of sites able to deliver a treatment can matter more than its efficacy for how many patients receive it, which favours simpler routes independently of clinical performance.
Devices Re-enter Where Biology Cannot Reach
Medium impactLong-termA subretinal photovoltaic implant showed clinically meaningful improvement in 81% of geographic atrophy participants at 12 months and is being evaluated in inherited retinal disease.
Insight: Patients with advanced photoreceptor loss are beyond gene therapy, so devices address a population that biological approaches structurally cannot, rather than competing with them.
Diagnosis Defines the Addressable Market
High impactMid-termEligibility for the one approved product requires confirmation of biallelic RPE65 mutations through genetic testing that is unevenly available.
Insight: The treatable population is set by testing coverage rather than by disease prevalence, so regional forecasting should track genetic diagnostic capacity rather than population.
Segment Analysis
Market segmentation by treatment type, end-user, route of administration, distribution channel
Only one of these five values contains an approved product, and understanding that is essential to reading this market. Gene Therapy holds the single approval, voretigene neparvovec for biallelic RPE65 mutations, which addresses between 0.23% and 4.27% of retinitis pigmentosa cases. Medications and Vitamin Supplements together account for most of what is actually spent, because the great majority of patients have no mutation-specific option and are managed with supplementation, monitoring and treatment of complications such as cystoid macular oedema and cataract. Stem Cell Therapy remains investigational, with small studies of mesenchymal cell implantation. Others covers low-vision rehabilitation and retinal prosthetics. The commercial shape of this market is therefore the inverse of its scientific interest: value sits in supportive care while attention sits in gene therapy.
Geography Analysis
Regional market analysis
North America
North America holds the only approval in this field and most of the clinical programmes behind it. Voretigene neparvovec was approved here in 2017 and remains the only approved gene therapy for the condition. The FDA has granted Fast Track designation to AAV-RPGR for X-linked disease, a rolling Biologics License Application for an optogenetic therapy is underway, and both the optogenetic and photovoltaic implant programmes are run from here. The regional ranking rests on that documented regulatory and clinical concentration rather than on a measured regional market size. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined discloses revenue attributable to retinitis pigmentosa, which is unsurprising given that one approved product serves a small fraction of an already rare disease.
Europe
Europe holds the marketing authorisation for the one approved gene therapy alongside North America, and contributes a share of the clinical development. The gene therapy programme for X-linked disease associated with RPGR variants has European roots, and the photovoltaic implant technology now being evaluated for inherited retinal disease originated in France before passing to its current owner. The region's health systems assess one-time high-cost gene therapies through health technology appraisal, which introduces a reimbursement step between approval and use that does not exist in the same form elsewhere. No European market size, revenue or growth figure was identified, and no company examined reports the region separately for this indication.
Asia Pacific
No market size, revenue or growth figure specific to Asia Pacific was identified for this market, and no company examined reports the region separately. The structural constraint here is genetic diagnosis rather than treatment supply. Retinitis pigmentosa is genetically heterogeneous, and eligibility for the one approved therapy depends on confirming biallelic RPE65 mutations, which requires genetic testing that is unevenly available. Where testing is absent, a patient cannot be identified as eligible regardless of whether the product is available in their country. Population size therefore predicts the prevalent patient count but not the treatable one, and the gap between the two is wider in this region than in North America or Europe.
Latin America
No market size, revenue or growth figure specific to Latin America was identified, and no company examined reports the region separately for this indication. With prevalence of 11.09 to 26.43 per 100,000, the region contains a substantial prevalent population, but the approved gene therapy requires both genetic confirmation of an RPE65 mutation and a centre capable of subretinal delivery during vitrectomy. Both are concentrated in few locations. The practical position is that management consists of supplementation, monitoring and treatment of complications, which places almost all regional activity in the Medications and Vitamin Supplements values rather than in Gene Therapy.
Middle East & Africa
No market size, revenue, prevalence or access figure specific to the Middle East and Africa was identified for this market. One structural factor is worth recording: retinitis pigmentosa includes autosomal recessive forms, whose frequency rises with consanguinity, so the prevalent population relative to births is likely higher in parts of the region than the global range of 11.09 to 26.43 per 100,000 would suggest. Against that, the region has the least access to the genetic testing that establishes eligibility and to the surgical centres that deliver subretinal therapy. The gap between prevalent and treatable population is therefore widest here of the five regions.
Competitive Landscape
Key players and market positioning analysis
This market has one approved product and a pipeline competing on how far it can escape the genetic heterogeneity that limits that product. Roche Holding AG holds voretigene neparvovec through Spark Therapeutics, approved in 2017 as the first gene therapy for inherited retinal dystrophy caused by biallelic RPE65 mutations and still the only approved gene therapy in retinitis pigmentosa. Its commercial ceiling is set by biology rather than by competition, since RPE65 accounts for between 0.23% and 4.27% of cases. Nanoscope Therapeutics, Inc. is the most advanced challenger with MCO-010, a bioengineered synthetic opsin delivered in an AAV2 vector to bipolar cells, which creates light sensitivity where photoreceptors have been lost and therefore works independently of the causative mutation. It is given as a single intravitreal injection rather than subretinally, has Fast Track and Orphan Drug designations, reported durable three-year vision improvements in the REMAIN study and five-year safety in EXTEND, and has a rolling Biologics License Application underway. MeiraGTx Holdings plc is developing botaretigene sparoparvovec, an AAV-RPGR therapy for X-linked disease, which holds Fast Track designation and is in the Lumeos phase 3 randomised controlled study. X-linked RPGR disease is a larger genetic subset than RPE65, so this programme would widen mutation-specific treatment rather than replace it. Science Corporation is pursuing a different route entirely with the PRIMA subretinal photovoltaic implant, a 2 by 2 millimetre array of 378 photovoltaic cells sensitive to near-infrared light. It reported clinically meaningful improvement in 81% of geographic atrophy participants at 12 months and is being evaluated in inherited retinal disease. Four participants are listed because the market contains few. The principal competitive factors are how much of the patient population an approach can address, the delivery route, and durability.
Major Players
Leading companies in the market
Industry Developments
5 recorded developments
The PRIMA subretinal photovoltaic implant reported that 81% of participants with geographic atrophy achieved clinically meaningful improvement at 12 months, and evaluation is being extended to inherited retinal diseases including retinitis pigmentosa.
Nanoscope Therapeutics reported three-year results from its REMAIN study showing durable vision improvements after a single intravitreal injection of MCO-010, with a favourable safety and tolerability profile maintained across the period.
Five-year follow-up from the EXTEND study confirmed MCO-010 as safe and well tolerated with no serious adverse effects and no new safety signals, alongside quality-of-life improvements. A rolling Biologics License Application for retinitis pigmentosa is underway.
The FDA granted Fast Track designation to AAV-RPGR for X-linked retinitis pigmentosa caused by defects in the RPGR gene, and the Lumeos phase 3 randomised controlled study of botaretigene sparoparvovec is actively dosing patients.
Voretigene neparvovec was approved in 2017 as the first gene therapy for inherited retinal dystrophy caused by biallelic RPE65 mutations. It remains the only approved gene therapy for retinitis pigmentosa, and it addresses a mutation accounting for between 0.23% and 4.27% of cases.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Treatment Type
5.3 By End-User
5.4 By Route of Administration
5.5 By Distribution Channel
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Roche Holding AG
9.2 Nanoscope Therapeutics, Inc.
9.3 MeiraGTx Holdings plc
9.4 Science Corporation
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Roche Holding AG, Nanoscope Therapeutics, Inc., MeiraGTx Holdings plc, Science Corporation + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.